No material catalyst from this filing. Monitor for UAE approval decisions and ex-U.S. revenue ramp, which could provide non-dilutive capital. Cash runway appears limited given $5.5M quarterly burn and $1.5M cash on hand.
Price Chart
Executive Summary
Evofem Biosciences reported Q1 2026 net sales of $0.9M (up from $0.8M YoY) but a net loss of $5.5M vs net income of $1.0M in Q1 2025, driven by a $5.6M one-time R&D expense reduction in the prior year. The company continues to burn cash with a stockholders' deficit of $77.6M and no analyst coverage, making this a routine quarterly update for a micro-cap biotech with no material catalyst.
Key Financial Metrics
Key Facts
- Q1 2026 net sales $0.9M vs $0.8M YoY (+12.5%)
- Net loss of $5.5M ($0.04/share) vs net income of $1.0M ($0.01/share) in Q1 2025
- Operating expenses $5.5M excluding a one-time $5.6M R&D trade payables settlement in prior year
- Cash and cash equivalents $1.5M, total current liabilities $78.8M, stockholders' deficit $77.6M
- No guidance provided; forward-looking statements cite limited cash resources and going concern risk
- Distribution agreement for SOLOSEC in Sub-Saharan Africa; UAE marketing approval review ongoing
Financial Impact
Revenue increased $0.1M YoY to $0.9M; net loss widened by $6.5M vs prior-year net income
Risk Factors
- Going concern risk with $77.6M stockholders' deficit and limited cash
- Dependence on ex-U.S. regulatory approvals and distributor performance for revenue growth
- No analyst coverage or consensus estimates to benchmark performance
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-024095 |
| Document: form8-k.htm | 0001493152-26-024095 |
| Document: 0001493152-26-024095-index-headers.html | 0001493152-26-024095 |
| Document: 0001493152-26-024095-index.html | 0001493152-26-024095 |
| Document: 0001493152-26-024095.txt | 0001493152-26-024095 |
| 8-K Data (Synthetic) | 0001493152-26-024095 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 15, 2026 11d ago | 8-K | $0.007000 | awaiting T+20 | — | $0.007000 (+0.00%) |
May 18, 2026 23w ago | 8-K | $0.007000 $0.007000 | · 0.00% | ▼ −1.58% | $0.007000 (+0.00%) |
Apr 30, 2026 25w ago | 8-K | $0.007000 $0.007000 | · 0.00% | ▼ −5.27% | $0.007000 (+0.00%) |
Mar 11, 2026 32w ago | 8-K | $0.009000 $0.009000 | · 0.00% | ▼ −1.98% | $0.007000 (−22.22%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers